Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study

Digestion

Volumn 79, Issue 3, 2009, Pages 137-142

  Kalinowski, Marc ^a   Dressler, Miriam ^a   König, Alexander ^a   El Sheik, Michael ^b   Rinke, Anja ^a   Höffken, Helmut ^a   Gress, Thomas M ^a   Arnold, Rudolf ^a   Klose, Klaus Jochen ^a   Wagner, Hans Joachim ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Vivantes Hospitals im Friedrichshain and Am Urban ^*  (Germany)

Author keywords

Liver metastases; Neuroendocrine tumors; Radioembolization; Selective internal radiation therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MACROSALB TC 99M; MICROSPHERE; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DUODENUM ULCER; FATIGUE; FEMALE; FOLLOW UP; HEPATIC ARTERY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LUNG SHUNTING; MALE; NAUSEA; NEUROENDOCRINE TUMOR; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; RADIATION SAFETY; SELECTIVE INTERNAL RADIATION THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; CITRATES; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; QUALITY OF LIFE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 62649150203     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209849     Document Type: Article

References (29)

1. Delcore R, Friesen SR: Gastrointestinal neuroendocrine tumors. J Am Coll Surg 2004; 178: 188-211.
2. Akerstrom G, Hellman P, Hessman O, et al: Management of midgut carcinoids. J Surg Oncol 2005; 89: 161-169.
3. Kaltsas GA, Besser GM, Grossman AB: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
4. Modlin IM, Kidd M, Latich I, et al: Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751.
5. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC: Update on the management of neuroendocrine hepatic metastases. J Vase In- terv Radiol 2006; 17: 1235-1249.
6. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
7. Sun W, Llpsitz S, Catalano P, Maillard JA, Haller DA: Phase II/III study of doxorubicin with fluorouracil compared with streptozo- cin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904.
8. Oberg K, Kvols S, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973.
9. Ruszniewski P, Malka D: Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000; 62(suppl l): 79-83.
10. Gupta S, Johnson MM, Murthy R, et al: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590-1602.
11. Murthy R, Xiong H, Nunez R, et al: Yttrium- 90 microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vase Interv Radiol 2005; 16: 937-945.
12. Kennedy AS, Coldwell D, Nutting C, et al: Resin 90Y microsphere brachytherapy for unresecatbale colorectal liver metastases: modern USA experience. Int J Rad Oncol Biol Phys 2006; 65: 412-425.
13. Murthy R, Nunez R, Szklaruk J, et al: Yt- trium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 2005; 25(suppl 1): S41-S55.
14. Gray B, Van Hazel G, Hope M, et al: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720.
15. Carr B: Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10(suppl 1): S107-S110.
16. Caldwell D: Use of yttrium-90 SIRSplieres to treat unresectable metastatic neuroendocrine tumors to the liver. Program and Abstracts of the World Congress on Gastrointestinal Cancer, Barcelona, 2005, abstr O-002.
17. Kennedy AS, Dezarn WA, McNeillie P, et al: Radioembolization for unresectable neuroendocrine hepatic metastases using resin Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
18. King J, Quinn R, Glenn DM, et al: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921-929.
19. Kennedy AS, Liu D, Dezarn AW, et al: Resin 90Y microsphere brachytherapy for unresectable neuroendocrine hepatic metastases. Am J Oncol Rev 2006; 4(suppl):l-8.
20. Salem R, Thurston KG: Radioembolization with 90-yttrium microspheres: a state-of- the-art brachytherapy treatment for primary and secondary liver malignancies. 1. Technical and methodologic considerations. J Vase Interv Radiol 2006; 17: 1251-1278.
21. Duffaud F, Therasse P: New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87: 881-886.
22. Aaronson NK, Ahmedzai S, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
23. Kavadas V, Blazeba JM, et al: Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer. Eur J Cancer 2003; 39: 1259-1263.
24. Veenendaal LM, Borel Rinkes IH, Lips CJ, et al: Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006; 4: 35-39.
25. Musunuru S, Chen H, Rajpal S, et al: Metastatic neuroendocrine hepatic tumors: resec tion improves survival. Arch Surg 2006; 141: 1000-1004.
26. Kress O, Wagner HJ, Wied M, et al: Transar- terial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-centre analysis. Digestion 2003; 68: 94-101.
27. Roche A, Girish BV, de Baere T, et al: Trans- catheter arterial chemoembolization as first- line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13: 136-140.
28. Ho AS, Picus J, Darcy MD, et al: Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007; 188: 1201-1207.
29. Steel J, Baum A, Carr B: Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrfum microspheres (therasphere). Psychooncology 2004; 13: 73-79.